Engineering and targeting potential of CAR NK cells in colorectal cancer.
10.1097/CM9.0000000000003346
- Author:
Muhammad Babar KHAWAR
1
;
Ali AFZAL
1
;
Shuangshuang DONG
1
;
Yue SI
1
;
Haibo SUN
1
Author Information
1. Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu 225009, China.
- Publication Type:Review
- Keywords:
Antigen targeting;
Chimeric antigen receptor;
Colorectal cancer;
Natural killer cells;
Resistance mechanisms;
Tumor microenvironment
- MeSH:
Colorectal Neoplasms/immunology*;
Humans;
Killer Cells, Natural/metabolism*;
Receptors, Chimeric Antigen/genetics*;
Immunotherapy, Adoptive/methods*;
Tumor Microenvironment/immunology*;
Animals
- From:
Chinese Medical Journal
2025;138(13):1529-1539
- CountryChina
- Language:English
-
Abstract:
Colorectal cancer (CRC), a major global health concern, necessitates innovative treatments. Chimeric antigen receptor (CAR) T cells have shown promises, yet they grapple with challenges. The spotlight pivots to the rising heroes: CAR natural killer (NK) cells, offering advantages such as higher safety profiles, cost-effectiveness, and efficacy against solid tumors. Nevertheless, the specific mechanisms underlying CAR NK cell trafficking and their interplay within the complex tumor microenvironment require further in-depth exploration. Herein, we provide insights into the design and engineering of CAR NK cells, antigen targets in CRC, and success in overcoming resistance mechanisms with an emphasis on the potential for clinical trials.
